Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study.
Hirofumi AkitaHidenori TakahashiHidetoshi EguchiKei AsukaiShinichiro HasegawaHiroshi WadaYoshifumi IwagamiDaisaku YamadaYoshito TomimaruTakehiro NodaKunihito GotohShogo KobayashiYuichiro DokiMasato SakonPublished in: Annals of gastroenterological surgery (2020)
CA19-9 and PET evaluation provided oncologically different risk assessments in terms of tumor recurrence profile, and favorable response in both CA19-9 and FDG-PET were necessary to achieve prognostic benefit from NACRT.